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Abstract
Background: The role of antiarrhythmic drugs for atrial fibrillation/atrial flutter
(AF/AFL) after catheter ablation is not well established.
Hypothesis: We hypothesized that changing the myocardial substrate by ablation
may alter the responsiveness to dronedarone.
Methods:We assessed the efficacy and safety of dronedarone in the treatment of par-
oxysmal/persistent atrial fibrillation/atrial flutter (AF/AFL) post-ablation, based on a
post hoc analysis of the ATHENA study. A total of 196 patients (dronedarone 90, pla-
cebo 106) had an ablation for AF/AFL before study entry. In these patients, the effect
of treatment on the first hospitalization because of cardiovascular (CV) events/all-
cause death was assessed, as was AF/AFL recurrence in individuals with sinus rhythm
at baseline. The safety of dronedarone vs placebo was also determined.
Results: In patients with prior ablation, dronedarone reduced the risk of AF/AFL
recurrence (hazard ratio [HR]: 0.65 [95% confidence interval [CI]: 0.42, 1.00]; P < .05)
as well as the median time to first AF/AFL recurrence (561 vs 180 days) compared
with placebo. The HR for first CV hospitalization/all-cause death with dronedarone
vs placebo was 0.98 (95% CI: 0.62, 1.53; P = .91). Rates of treatment-emergent
adverse events were 83.1% vs 75.5% and rates of serious TEAEs were 27.0% vs
18.9% in the dronedarone and placebo groups, respectively. One death occurred with
dronedarone (not treatment-emergent) and five occurred with placebo.
Conclusion: In patients with prior ablation for AF/AFL, dronedarone reduced the risk of
AF/AFL recurrence compared with placebo, but not the risk of first CV hospitalization/
all-cause death. Safety outcomeswere consistentwith those of the overall ATHENA study.
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1 | INTRODUCTION
Antiarrhythmic drugs (AADs) have commonly been used as first-line
treatment for maintenance of sinus rhythm in individuals with parox-
ysmal and persistent atrial fibrillation (AF), and form a class IA recom-
mendation in the American Heart Association (AHA)/American
College of Cardiology (ACC)/Heart Rhythm Society (HRS) AF guide-
lines.1,2 Real-world data indicate an increasing use of catheter ablation
for rhythm management of AF,3,4 driven by improvements in ablation
techniques and outcomes.5 In addition, recently completed clinical
studies (including “Catheter Ablation vs Standard Conventional Treat-
ment in Patients With LV Dysfunction and AF” [CASTLE-AF;
NCT00643188] and “Catheter Ablation vs Antiarrhythmic Drug Ther-
apy in Atrial Fibrillation” [CABANA; NCT00911508]), comparing out-
comes with first-line catheter ablation vs medical therapy, support the
safety of catheter ablation and highlight the potential for earlier abla-
tion in selected patients.6,7
The use of AADs and catheter ablation are not mutually exclu-
sive.1,2,5 AADs are often used immediately following ablation to
reduce the risk of early AF recurrence,8-10 and may be used in the
long term depending on patient and physician preference.5 Successful
ablation may alter the responsiveness to AADs,11 possibly as a result
of changes to the substrate within the atrium and the triggers for
AF. However, there is a substantial gap in scientific evidence regard-
ing the impact of ablation on the effectiveness and safety of AADs in
the post-ablation setting.
Dronedarone is an AAD that has been shown to reduce the rate
of hospitalization because of cardiovascular (CV) events in patients
with paroxysmal or persistent AF or atrial flutter (AFL) in a random-
ized, double-blind, placebo-controlled phase 3 study (“A Trial with
Dronedarone to Prevent Hospitalization or Death in Patients with
Atrial Fibrillation” [ATHENA; NCT00174785]).12 The aim of the cur-
rent analysis was to assess the efficacy and safety of dronedarone
among patients with prior ablation who received treatment in the
ATHENA study.
2 | METHODS
2.1 | Overview of the ATHENA study
ATHENA was a randomized, double-blind, placebo-controlled study
conducted in 4628 patients in 551 centers across 37 countries.
Details of the study design have been described previously.12,13 Ini-
tially, patients were eligible for inclusion if they were at least 70 years
of age or had a specified CV risk factor. In order to enrich the risk pro-
file of patients, inclusion criteria were amended during the study to
allow only patients ≥75 years old or ≥70 years old with at least one
additional CV risk factor. Patients who experienced AF/AFL
<6 months before randomization (based on 12-lead electrocardiogram
[ECG]) could be included if they had a second ECG showing sinus
rhythm during this period. Patients could be enrolled while in sinus
rhythm if conversion had occurred either spontaneously or after
electrical or pharmacologic cardioversion. Patients enrolled while in
AF/AFL were expected to undergo cardioversion after appropriate
anticoagulation treatment.
Patients were randomized in a 1:1 ratio to dronedarone 400 mg
twice daily or placebo in addition to their rate-control therapy; the
minimum follow-up period was 12 months. The primary efficacy end-
point was first hospitalization because of CV events or death from
any cause. Secondary endpoints included death from any cause, CV
death and first CV hospitalization. The study was approved by the
independent review board at each participating site and was con-
ducted according to the Declaration of Helsinki. All patients provided
written informed consent before participating in the study. Patient
enrollment started in June 2005 and was completed in December
2006.
2.2 | Post hoc analysis
This analysis focused on patients who had received any ablation pro-
cedure for AF/AFL before randomization in the ATHENA study and
subsequently received study treatment. The primary and secondary
endpoints of the ATHENA study were assessed in this patient popula-
tion. First recurrence of AF/AFL was assessed in patients who were in
sinus rhythm at baseline. In addition, the effect of ablation status on
the incidence of treatment-emergent adverse events (TEAEs) occur-
ring from first study drug intake up to last study drug intake plus
10 days was assessed.
2.3 | Assessments
Clinical evaluations, categorization for unplanned hospitalizations
(CV or non-CV), deaths (non-arrhythmic cardiac, arrhythmic cardiac,
non-cardiac vascular, or non-CV) and safety assessments were con-
ducted as described previously.12
Scheduled 12-lead ECGs were recorded at 7 and 14 days, and at
1, 3, and 6 months after randomization, then every 6 months thereaf-
ter. In addition, ECGs were recorded during unscheduled visits, such
as in patients presenting with recurrent symptoms. Each ECG was
classified by the investigator as demonstrating AF, AFL or sinus
rhythm. AF/AFL recurrence was determined to occur at the first
instance of cardioversion, AF/AFL based on electrocardiography or
hospitalization for AF/AFL, as described previously.14
Patient baseline and demographic characteristics were reviewed
for patients with and without ablation before study randomization.
2.4 | Statistical analysis
For the primary endpoint, cumulative incidence functions in each
treatment group were calculated and plotted using the Kaplan-Meier
method. Unadjusted hazard ratios (HRs) and 95% confidence intervals
(CIs) were estimated using an unstratified Cox regression model with
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treatment group as the only factor. A multivariate analysis was consid-
ered unsuitable based on the small patient population and multiple
biases associated with a post hoc analysis. Data were analyzed using
SAS version 8.2 or later (Cary, North Carolina). Potential interaction
between treatment (ie, dronedarone or placebo) and ablation status
(ie, prior ablation or no prior ablation) was assessed using a Cox
regression model for occurrence of first TEAE applied to the whole
study safety population. An independent data and safety monitoring
board provided regular reviews of study data.
3 | RESULTS
3.1 | Baseline and demographic characteristics
Among the 4628 patients randomized in the ATHENA study,
217 (4.7%) had received any ablation procedure before randomization,
including 196 (4.2%) who had an ablation for AF/AFL. The proportion
of patients who received ablation for AF/AFL before randomization
was similar in the dronedarone (90 of 2301 patients; 3.9%) and pla-
cebo (106 of 2327 patients; 4.6%) groups (Table 1).
Patient baseline and demographic characteristics in the
dronedarone and placebo groups among patients with and without
prior ablation are shown in Table 2. Among patients who had received
prior ablation for AF/AFL, baseline and demographic characteristics
were similar in the dronedarone and placebo groups.
3.2 | Efficacy
Median follow-up for patients who received ablation for AF/AFL was
666 days in those treated with dronedarone and 688 days in those
treated with placebo.
In patients with prior ablation, first CV hospitalization or death
from any cause occurred in 35 of 90 patients (38.9%) randomized to
dronedarone and in 42 of 106 patients (39.6%) randomized to placebo
(HR: 0.98 [95% CI: 0.62, 1.53]; P = .91; Table 3). HR values for first
CV hospitalization, death from any cause, and CV death were 1.05
(95% CI: 0.67, 1.66), 0.26 (95% CI: 0.03, 2.2) and 0.68 (95% CI: 0.06,
7.5), respectively (Table 3).
The most common cause of first CV hospitalization was
AF/supraventricular rhythm disorders, accounting for 37% of first CV
hospitalizations with dronedarone and 46% with placebo (Table S1).
One death (because of cardiogenic shock) occurred in the
dronedarone group and was not treatment-emergent; five deaths
(two sudden cardiac deaths, and one case each because of pneumo-
nia, pancreatic adenocarcinoma, and multi-organ failure) occurred in
the placebo group.
Among the 128 patients who were in sinus rhythm at baseline,
AF/AFL recurrence occurred in 36 of 63 patients (57.1%) treated with
dronedarone and 46 of 65 patients (70.8%) treated with placebo
(Table 3). Median time to first AF/AFL recurrence was longer
(561 days [95% CI: 342, 778] vs 180 days [95% CI: 61, 429]) and risk
of first AF/AFL recurrence was lower in patients treated with
dronedarone compared with placebo (HR: 0.65 [95% CI: 0.42, 1.00],
P < .05; Table 3; Figure 1).
3.3 | Safety
TEAEs occurred in 83.1% and 75.5% of patients treated with
dronedarone and placebo, respectively (Table 4). The most common
TEAEs in the dronedarone and placebo groups were dizziness (12.4%
vs 16.0%), diarrhea (14.6% vs 8.5%) and nausea (11.2% vs 3.8%). Seri-
ous TEAEs occurred in 27.0% of patients receiving dronedarone and
in 18.9% of patients receiving placebo. Permanent study drug discon-
tinuations because of adverse events (AEs) occurred in 10.1% of
patients receiving dronedarone and 15.1% of patients receiving pla-
cebo. Using the Cox proportional hazard regression model on the
whole study population, no evidence of interaction was shown
between treatment (ie, dronedarone or placebo) and ablation status
for occurrence of first TEAE (P = .44) or first serious TEAE (P = .14).
4 | DISCUSSION
In this analysis, dronedarone treatment decreased the risk of first
AF/AFL recurrence compared with placebo in patients who had
received catheter ablation before randomization, and demonstrated a
safety profile similar to that observed in the overall ATHENA popula-
tion.12 The rate of AF/AFL recurrence was 57% in the dronedarone
group vs 71% in those treated with placebo.
The rates of first CV hospitalization or death from any cause
(39% in the dronedarone group and 40% in the placebo group) in
patients with prior ablation were in fact similar to those observed in
the placebo arm of the overall ATHENA population (39%),12 and indi-
cate a residual high burden of CV morbidity and mortality in these
patients. For patients with prior ablation who were randomized to
TABLE 1 Ablation status before randomization in the ATHENA
study
Ablation status,
n (%)
Dronedarone
(n = 2301)
Placebo
(n = 2327)
All
(N = 4628)
No ablation 2203 (95.7%) 2208 (94.9%) 4411 (95.3%)
Ablation for
AF/AFL
90 (3.9%) 106 (4.6%) 196 (4.2%)
Ablation only
for AF/AFL
86 (3.7%) 102 (4.4%) 188 (4.1%)
Ablation for
both AF/AFL
and for other
reason
4 (0.2%) 4 (0.2%) 8 (0.2%)
Ablation only for
reason other
than AF/AFL
8 (0.3%) 13 (0.6%) 21 (0.5%)
Abbreviations: AF, atrial fibrillation; AFL, atrial flutter.
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dronedarone, this outcome was driven predominantly by first CV hos-
pitalization, with only one death from any cause. The most common
causes of first CV hospitalization were AF/supraventricular rhythm
disorders, which were numerically lower with dronedarone than with
placebo.
Baseline and demographic characteristics of patients having prior
ablation were broadly similar across the dronedarone and placebo
groups. As expected, patients who had undergone ablation before
randomization appeared more likely to be receiving an oral
anticoagulant (77% vs 59%) and to have more extensive CV disease,
including clinical tachycardia (52% vs 33%), a pacemaker implantation
(28% vs 9%), cardiac valve surgery (13% vs 3%) or an implanted car-
dioverter defibrillator (8% vs 2%) at baseline than patients without
ablation. Despite these differences, safety observations in patients
with prior ablation were largely consistent with those in the overall
ATHENA study.12 Relative risk analysis suggested no interaction
between ablation status and treatment for either TEAEs or serious
TEAEs.
TABLE 2 Patient baseline and demographic characteristics according to treatment group and prior ablation in the ATHENA study
Patients with ablation for AF/AFL Patients with no ablation
Dronedarone
(n = 90)
Placebo
(n = 106)
Dronedarone
(n = 2203)
Placebo
(n = 2208)
Age, mean years (SD) 70.1 (9.1) 68.2 (9.2) 71.6 (8.9) 71.8 (9.0)
Sex, male patients, n (%) 57 (63.3) 77 (72.6) 1109 (50.3) 1204 (54.5)
Race, n (%)
White 77 (85.6) 96 (90.6) 1982 (90.0) 1965 (89.0)
Black 3 (3.3) 2 (1.9) 16 (0.7) 29 (1.3)
Asian 7 (7.8) 8 (7.5) 141 (6.4) 144 (6.5)
Other 3 (3.3) 0 (0) 64 (2.9) 70 (3.2)
Cardiovascular history, n (%)
Hypertension 76 (84.4) 84 (79.2) 1915 (86.9) 1904 (86.2)
Structural heart disease 56 (62.2) 69 (65.1) 1267a (58.0) 1324b (60.6)
Tachycardia 46 (51.1) 56 (52.8) 703 (31.9) 731 (33.1)
Coronary heart disease 26 (28.9) 37 (34.9) 631 (28.6) 686 (31.1)
Non-rheumatic valvular heart disease 20 (22.2) 20 (18.9) 311 (14.1) 330 (14.9)
Pacemaker 23 (25.6) 31 (29.2) 188 (8.5) 211 (9.6)
Lone AF 3 (3.3) 8 (7.5) 137c (6.2) 130c (5.9)
Ischemic dilated cardiomyopathy 6 (6.7) 11 (10.4) 85 (3.9) 106 (4.8)
Supraventricular tachycardia other than AF/AFL 8 (8.9) 7 (6.6) 84 (3.8) 79 (3.6)
Cardiac valve surgery 9 (10.0) 16 (15.1) 71 (3.2) 78 (3.5)
Non-ischemic dilated cardiomyopathy 5 (5.6) 10 (9.4) 77 (3.5) 74 (3.4)
Hypertrophic cardiomyopathy 5 (5.6) 1 (0.9) 38 (1.7) 48 (2.2)
Implanted cardioverter defibrillator 4 (4.4) 11 (10.4) 37 (1.7) 31 (1.4)
Rheumatic valvular heart disease 2 (2.2) 5 (4.7) 49 (2.2) 24 (1.1)
Baseline cardiovascular examination, n (%)
LVEF <35% 5d (5.7) 7 (6.6) 87e (4.0) 80f (3.7)
Chronic heart failure symptoms (NYHA Class ≥1) 24 (26.7) 23 (21.7) 645 (29.3) 666 (30.2)
Baseline medications, n (%)
Beta blockers (except sotalol) 66 (73.3) 72 (67.9) 1556 (70.6) 1560 (70.7)
ACE/angiotensin II inhibitor 56 (62.2) 72 (67.9) 1551 (70.4) 1522 (68.9)
Oral anticoagulant 69 (76.7) 81 (76.4) 1331 (60.4) 1293 (58.6)
Low-dose aspirin 29 (32.2) 41 (38.7) 986 (44.8) 972 (44.0)
Statin 30 (33.3) 52 (49.1) 846 (38.4) 857 (38.8)
Calcium antagonist with heart-rate-lowering effect 17 (18.9) 18 (17.0) 314 (14.3) 286 (13.0)
Digitalis 17 (18.9) 18 (17.0) 304 (13.8) 287 (13.0)
Note: Denominators for calculation of percentages; an = 2184; bn = 2185; cn = 2199; dn = 87; en = 2169; fn = 2162.
Abbreviations: ACE, angiotensin-converting enzyme; AF, atrial fibrillation; AFL, atrial flutter; LVEF, left ventricular ejection fraction; NYHA, New York
Heart Association.
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With the increasing use of ablation to achieve rhythm control in
patients with AF,3,4 positioning of AADs and ablation in specific
patient populations is of considerable practical importance. In current
AHA/ACC/HRS guidelines, AADs remain a first-line treatment recom-
mendation for patients with paroxysmal and persistent AF, with
choice of AAD depending on underlying heart disease and com-
orbidities.1,2 Both AHA/ACC/HRS guidelines1,2 and an expert consen-
sus from HRS/EHRA/ECAS/APHRS/SOLEACE5 consider catheter
ablation as a class IA recommendation in patients with symptomatic
paroxysmal AF who are refractory or intolerant to at least one class I
or III AAD, and as a IIaB recommendation as first-line treatment in
patients with paroxysmal AF, prior to initiation of an AAD.
In real-world evaluations, fewer than 50% of patients achieve
treatment success at 1 year following catheter ablation, based on
freedom from AF recurrence without the use of AADs.15,16 Data
from the ESC-EHRA AF ablation long-term registry show that for
patients receiving ablation, 90% had received AAD treatment before
ablation, 68% received AADs shortly after ablation and 46% were on
AADs at 1-year follow-up.17 In the CABANA study, a high incidence
of crossovers between the ablation and medical therapy arms high-
lights the difficulty in separating ablation and medical therapies for
AF rhythm management.7 Furthermore, almost 50% of patients in
the ablation arm of the CABANA study had AF recurrences at
4 years, emphasizing the need to explore efficacy and safety of AAD
treatment as complementary rather than competing approaches to
rhythm management.
While short-term adjunctive AAD therapy has been shown to sig-
nificantly reduce the risk of early AF recurrence compared with abla-
tion alone,9 there are few randomized controlled trials and real-world
data addressing outcomes with AADs in patients with prior ablation,
and the efficacy and safety of AADs in this setting are unclear.5,18,19
Data from a large, single-center study in 439 patients with paroxysmal
or persistent AF suggest that shortened time to recurrence after abla-
tion is linked to an increased responsiveness to AADs, possibly as a
result of substrate changes, making reintroduction of AAD therapy
after ablation a compelling option.11
4.1 | Limitations
The ATHENA study was not designed or powered to detect differ-
ences in efficacy or safety of dronedarone vs placebo within the sub-
set of patients with prior ablation. As a post hoc analysis, and with a
relatively small number of patients, this study should be regarded as
exploratory. Furthermore, information was not available on either the
timing or characteristics of prior ablation, the type of AF/AFL for indi-
vidual patients at randomization, or heart rate during sinus rhythm
and AF episodes throughout the study.
TABLE 3 Efficacy of dronedarone vs placebo in patients with ablation for AF/AFL before randomization in the ATHENA study
Event
No. of events/
no. at risk
Median time to event,
days (95% CI)
DRO PBO DRO PBO Hazard ratio (95% CI) P-value
First CV hospitalization or death from any cause 35/90 42/106 NR NR 0.98 (0.62, 1.53) .91
First CV hospitalization 35/90 39/106 NR NR 1.05 (0.67, 1.66) .83
Death from any cause 1/90 5/106 NR NR 0.26 (0.03, 2.2) .18
CV death 1/90 2/106 NR NR 0.68 (0.06, 7.5) .75
First AF/AFL recurrencea 36/63 46/65 561 (342, 778) 180 (61, 429) 0.65 (0.42, 1.00) .048
Abbreviations: AF, atrial fibrillation; AFL, atrial flutter; CI, confidence interval; CV, cardiovascular; DRO, dronedarone; NR, not reached; PBO, placebo.
aOnly patients in sinus rhythm at baseline included.
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5 | CONCLUSION
In this post hoc analysis, dronedarone delayed the time to first
AF/AFL recurrence in the subset of ATHENA patients with prior cath-
eter ablation, with safety outcomes consistent with those of the over-
all ATHENA study. These data are hypothesis-generating and support
further evaluation of dronedarone in the post-ablation setting in ade-
quately sized prospective studies.
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